æ ¶æçŸ©å¡Ÿå€§åŠ(æ ¶å¿å€§)ã¯5æ21æ¥ãè³æ¢å¡åŸã®ççåå¿ãåŒãèµ·ããè³å å åãæ°ãã«çºèŠãããã®è³å å åã®æŽ»æ§ãæãããšæ¢å¡é åãçž®å°ããç¥çµçç¶ãæ¹åããããšã確èªãããšçºè¡šããã
ææã¯ãå倧ã®äžç°åŽ(ã·ãã¿ã»ã¿ã«ã·)婿ãååææåœŠææãã®ç ç©¶ã°ã«ãŒãã«ãããã®ãç ç©¶ã¯ãJST課é¡éæååºç€ç ç©¶ã®äžç°ãšããŠè¡ããããç ç©¶ã®è©³çްãªå 容ã¯ãè±åœæé5æ20æ¥ä»ãã§è±ç§åŠéèªãNature Medicine ããªã³ã©ã€ã³çã«æ²èŒã
è³æ¢å¡ã¯ãè³ã®è¡ç®¡ãè©°ãŸããªã©ããŠè³è¡æµãä¹ãããªãããš(èè¡)ã«ãã£ãŠè³çµç¹ã壿»ã«é¥ãç æ ã ãæ¥æ¬ã§ã¯æ£è ç·æ°96äžäººãšããããããã«å¹æµããæ£è æ°ã (åçåŽåçãå¹³æ20幎æ£è 調æ»ããã)ã
ãããŠãè³æ¢å¡ã®æ»äº¡è æ°ã¯å¹ŽéçŽ7äžäºº(åçåŽåçãå¹³æ22幎人å£åæ çµ±èšããã)ã§ãæ»äº¡çãé«ãã ãã§ãªããå©ãã£ãŠãå¯ãããã«ãªããªã©æ£è ã®ç掻ã®è³ª(QOL)ãéåžžã«æªãããšãç¹åŸŽã§ããã
ãããŸã§ã®è³æ¢å¡ã®æ²»çã¯çºççŽåŸ(4.5æé以å )ã«ãè¡æ 溶解è¬ããæäžãããªã©ãéãããæ²»çæ³ãããªãã£ããããããæ¢å¡åŸåŸã ã«ççãèµ·ãã£ãŠè³çµç¹ãæµ®è «ãèµ·ãããŠè «ããããšã«ãããæ¢å¡é åãåºãã£ãããç ç¶ãæªåãããããããšããããããããæå¶ããããšãéèŠãšèããããŠããã
è³çµç¹ã«ççãèµ·ãããšã壿»ããçµç¹ã®äžã«è¡æ¶²ç±æ¥ã®å ç«çްè(ããã¯ããã¡ãŒãžããããªã³ãçã)ã倿°ååšãããªããã€æŽ»æ§åããããããççæ§å åãç£çããããšã«ãã£ãŠããã«ççãä¿é²ãããŠããŸãããã®çµæã壿»ããçµç¹åšå²ã®æ£åžžçµç¹ãå·ã€ããŠæ¢å¡é åãæ¡å€§ãããŠããŸããšããããã (ç»å1)ã
ç¹ã«ããã¯ããã¡ãŒãžã¯çºçæ©æã«æµžæœ€ããççãã¹ã¿ãŒããããã«ã®ã®çްèãšãªã£ãŠããããããããã¯ããã¡ãŒãžãã©ã®ãããªæ©æ§ã§æŽ»æ§åãããã®ãã¯ãŸã£ããäžæã ã£ãã
ãããŸã§ã®ç ç©¶ã§ããã¯ããã¡ãŒãžã现èãèªèããã®ã«äœ¿ã£ãŠãããTollæ§å容äœ(Toll-like receptor:TLR)ãããè³æ¢å¡åŸã®ççã«ã¯å¿ èŠã ãšããããšãããã£ãŠããã
ãªãTollæ§å容äœãšã¯ãèªç¶å ç«ã®æ©èœãæã€å容äœã ãäž»ã«çްèã®ãªãå€ç³ããªãã¿ã³ãã¯è³ªããŠã€ã«ã¹ç±æ¥ã®DNAãRNAãèªèããŠçްèå ã·ã°ãã«ãäŒããããšã«ãããããŸããŸãªå ç«å¿çãåŒãèµ·ãããçµç¹å·å®³ã«ãã£ãŠæŸåºãããDAMPsãèªèããå容äœãšããŠã泚ç®ãããŠããã
ãããè³ã¯ç¡èçã§ã¯ãªãŒã³ãªèåšã§ããã现èããŠã€ã«ã¹ãªã©ã®å€æµã¯éåžžååšããªããåŸã£ãŠãTLRã«èªèãããäœããã®ç©è³ªãè³çµç¹ã®äžã«ããšããšååšããŠããããã®ç©è³ªã¯è³çµç¹ã壿»ã«é¥ã£ãæã«çްèå€ã«ã°ããŸãããŠãTLRãä»ããŠãã¯ããã¡ãŒãžãåºæ¿ããŠæŽ»æ§åããããšèããããã®ã ã
ãã®ãããªç©è³ªã¯ãããã¡ãŒãžé¢é£ååãã¿ãŒã³(Damage-associated molecular patterns:DAMPs)ããšåŒã°ããŠããããã ãããããŸã§è³å ã®DAMPsã¯äžæã§ãæ²»çã®æšçã«ãªãåŸããã©ãããããã£ãŠããªããç¶æ³ã ã
ãã¡ãŒãžé¢é£ååãã¿ãŒã³ãšã¯ãçµç¹å·å®³ã«äŒŽã£ãŠçްèããæŸåºãããåšå²ã®çµç¹ã现èã«å±éºãç¥ãããã¢ã©ãŒã ã®ãããªåœ¹å²ãæ ãå åã®ããšãã¿ã³ãã¯è³ªãHMGB1(High mobily group box1)ãããç±ã·ã§ãã¯ã¿ã³ãã¯è³ª(Heat shock protein:HSP)ããåç²§åãå»è¬åãªã©ã§ã«å«ãŸããŠããŠä¿æ°Žå¹æã§ç¥ãããããã¢ã«ãã³é žãããé žååLDL(Low Density Lipoprotein cholesterol:æªçã³ã¬ã¹ãããŒã«)ããªã©ãDAMPsãšããŠæ©èœããããšãç¥ãããŠããã
ä»åãç ç©¶ã°ã«ãŒãã¯è³çµç¹äžã«ååšããæ°èŠã®DAMPsãšããŠããã«ãªãã·ã¬ããã·ã³(peroxiredoxin:Prx)ããåå®ããã®Prxã壿»ããè³çµç¹ã®äžã§æŸåºãããçµæãšããŠæµžæœ€ãããã¯ããã¡ãŒãžã掻æ§åãããççãåŒãèµ·ãããŠããããšãçºèŠãããã®ã§ããã
ãªããã«ãªãã·ã¬ããã·ã³ãšã¯ããããŸã§ã¯çŽ°èæ¯ã§ãããéé žåæ°ŽçŽ (H2O2)ããªã©ã®æŽ»æ§é žçŽ çš®ãç¡æ¯åããæé žåé µçŽ ãšããŠã现èãé«çæ€ç©ã®çްèå ã«ãååšããããšãç¥ãããŠããŠãããåºä¹³åç©ã§ã¯ãããŸã§ã«ãPrx1ïœPrx6ã®6çš®é¡ã®Prxãã¡ããªãŒã¿ã³ãã¯è³ªãåå®ãããŠããã
å®éšã§ã¯ããŸãè³çµç¹ã®æœåºæ¶²ãäœè£œãããããå¹é€ãããã¯ããã¡ãŒãžãšåæ§ãªæ©èœãæã€ãæš¹ç¶çްèãã«æ·»å ããããšãããŸããŸãªãççæ§ãµã€ãã«ã€ã³ã(ãIL-23ãããIL-1βãããTNF-αããªã©)ãç£çããããšã倿ã
è³æœåºæ¶²ããã¿ã³ãã¯è³ªåè§£é µçŽ ã§åŠçãããšæŽ»æ§èœåããªããªãããšãããè³æœåºæ¶²äžã®æš¹ç¶çްèãæŽ»æ§åããç©è³ªã¯ã¿ã³ãã¯è³ªã§ããããšã確ããããããããã§ãè³æœåºæ¶²ãããŸããŸã«åç»ãæçµçã«è³ªéåæèšãçšããè§£æã«ãã£ãŠããPrxãã¡ããªãŒãã¿ã³ãã¯è³ªãæš¹ç¶çްèãæŽ»æ§åããŠããããšãçªããšããããã®ã§ãã(ç»å2)ã
ãªããç»å2ã®èŠæ¹ã¯ã(1)è³ãããæœ°ããæœåºæ¶²ãæš¹ç¶çްèã«æ·»å ãããšççæ§ãµã€ãã«ã€ã³ã®äžçš®ã§ããIL-23ãç£çããããã¿ã³ãã¯è³ªåè§£é µçŽ ã§åŠçããè³æœåºæ¶²ã§ã¯IL-23ã¯èªå°ãããªãã(2)è³æœåºæ¶²ãã·ã§ç³æ¿åºŠåŸé ã«ãã£ãŠååéã§åç»ãããšã15ïœ25kDaã®åç»ã«IL-23èªå°æŽ»æ§ãããããšãããã£ããIL-23èªå°æŽ»æ§ã®ããåç»ã質éåæèšã§è§£æããåè£ãšãªãã¿ã³ãã¯è³ªãåå®ãããã(3)ã¿ã³ãã¯è³ªããªã³ã³ããã³ãããäœè£œããæš¹ç¶çްèã«æ·»å ãããšããPrxãã¡ããªãŒã¿ã³ãã¯è³ªã«åŒ·ãIL-23èªå°æŽ»æ§ãèªããããã
ã¡ãªã¿ã«Prxãã¡ããªãŒã¿ã³ãã¯è³ªã¯ã现èããåºä¹³é¡ãŸã§å¹ åºãååšããéåžžã¯çްèå ã«ãã£ãŠéé žåæ°ŽçŽ ãæ°Žã«å€æããé žå鲿¢é µçŽ ã ãåŸã£ãŠãèè¡ãªã©ã®ã¹ãã¬ã¹ã®éã«ã¯å€§éã«åæãããŠã现èå ã®éé žåæ°ŽçŽ ãæ°Žã«å€æããŠçްèãä¿è·ããåãããããšèããããŠããã
ãããã现èã壿»ãããšPrxã¯çްèã®å€ã«æŸåºãããŠããŸããèè¡ã«é¥ã£ãè³çµç¹ã§ã¯ã壿»ããçµç¹ã®åšãã«Prxãå«ã现èã®æ®éªžãéç©ããŠãããããã«ãã¯ããã¡ãŒãžãšæ¥è§ŠããŠããããšãçºèŠããã(ç»å3)ã
ç»å3ã¯ãPrxã¯çްèå€ã«æŸåºãããŠãã¯ããã¡ãŒãžãåºæ¿ããŠããæ§åãçºç1æ¥ç®ã®æ¢å¡äžå¿ã«ãããå ç«æè²åã瀺ãã(å·Š)Prx6ãé«çºçŸããå€éã®ãdebrisã(壿»ããçµç¹ã®æ®éªž)ãååšãã(ç·è²)ã(äž)F4/80éœæ§çްè(ãã¯ããã¡ãŒãž)ãè³å ã«æµžæœ€ããŠãã(èµ€è²)ã(å³)Prx6ãå«ãdebrisããã¯ããã¡ãŒãžã®çްè衚é¢äžã«å ±å±åšããŠããã
ãããã®ããšã¯ãèè¡ã¹ãã¬ã¹ã®éã«çްèãçåãããããã«çްèå ã§PrxãçºçŸãããããçŽ°èæ»ã«è³ããšPrxã¯çްèå€ã«æŸåºãããåšå²ã«æµžæœ€ãããã¯ããã¡ãŒãžã掻æ§åããã¡ã«ããºã ããããšããããšã (ç»å4)ã
ç»å4ã¯ãPrxã现èå å€ã§ç°ãªãåããæã€ããšã衚ããæš¡åŒå³ãPrxã¯éé žåæ°ŽçŽ (H2O2)ãæ°Ž(H2O)ã«ä»£è¬ãããèè¡ã¹ãã¬ã¹ã«ãã£ãŠçްèå ã®éé žåæ°ŽçŽ ãå¢ãããšãPrxã现èå ã§çºçŸãããŠéé žåæ°ŽçŽ ã代è¬ããããšã«ããã现èãçåããããããã现èã壿»ãããšã现èå ã®Prxã¯ãdebrisããšå ±ã«çްèå€ã«æŸåºãããŠãè³å ã«æµžæœ€ãããã¯ããã¡ãŒãžã«TLR2ãšTLR4ãä»ããŠäœçšãã(DAMPsãšãªã)ã
|
|
|
ç»å3ãPrxã¯çްèå€ã«æŸåºãããŠãã¯ããã¡ãŒãžãåºæ¿ããŠããæ§å |
ç»å4ãPrxã现èå å€ã§ç°ãªãåããæã€ããšã衚ããæš¡åŒå³ |
å®éã«Prxãæš¹ç¶çްèãæŽ»æ§åããã¡ã«ããºã ã調ã¹ãŠèŠããšãPrxã¯æš¹ç¶çްèã®è¡šé¢ã«ååšããTLR2ãTLR4ãä»ããŠãã¯ããã¡ãŒãžã掻æ§åãããŠããããšã倿ããã
Prxã®å€ç°äœãäœè£œããŠãæš¹ç¶çްèãæŽ»æ§åããã®ã«å¿ èŠãªæ§é ã調ã¹ãããããããšãPrxãã¡ããªãŒã¿ã³ãã¯è³ªã«å ±éããŠååšããæ§é ãα3-helixããTLR2ãTLR4ãä»ããŠãã¯ããã¡ãŒãžã掻æ§åãããŠããããšã確èªãããã®ã§ãã(ç»å5)ã
次ã«ã现èå€ã«æŸåºãããPrxã®æŽ»æ§ãé€å»ããããã«äžåæäœãäœè£œãããããã®æäœã¯ã詊éšç®¡å ã§è³æœåºæ¶²ã®æš¹ç¶çŽ°èæŽ»æ§åèœãååä»¥äžæå¶ã§ããããšãããã£ãã
ãã®Prxæäœããäžéæ§è³èè¡ã¢ãã«ãããŠã¹ã«æäžãããšãããè³çµç¹ã§ã®ççæ§ãµã€ãã«ã€ã³ãæããããæ¢å¡äœç©ãçž®å°ããç¥çµçç¶ãèããæ¹åããã®ã確ãããããã®ã§ãã(ç»å6)ã
ãªããäžéæ§è³èè¡ã¢ãã«ãšã¯ãè³æ¢å¡ã®åç©ã¢ãã«ã®ããšã ãè³è¡ç®¡ãéå¡ããæ¹æ³ã¯å€æ°ããããä»åã®ç ç©¶ã§ã¯ã现ã塿 糞ãé åèããæ¿å ¥ããŠè³è¡ç®¡(äžå€§è³åè)ã«å°éãããéå¡ãããææãçšãããããæ¿å ¥ãã塿 糞ãåŒãæãããšã«ãããè³è¡ç®¡ã®éå¡ãè§£é€ãããããšãã§ããããã®ãããäžéæ§èè¡åéæµã¢ãã«ããšãåŒã°ããã
ç»å6ã¯ãäžéæ§è³èè¡ã¢ãã«ããŠã¹ã«ãããPrxæäœãHMGB1æäœæäžã®å¹æããŸãšãããã®ãè³èè¡èªå°çŽåŸã«æPrxæäœãæHMGB1æäœããŸãã¯ãã®äž¡æ¹ãæäžããŠã(a)çºç4æ¥ç®ã®æ¢å¡äœç©(æè²åã¯MAP2æè²:çœãéšåãæ¢å¡å·£ã瀺ã)ã(b)çºççŽåŸãã3æ¥ç®ãŸã§ã®ç¥çµçç¶ã®æšç§»ã瀺ã(:PïŒ0.05ã * *:PïŒ0.001vså¯Ÿç §çŸ€)ã
ããŸããŸãªççã§HMGB1ããDAMPs(ãã¡ãŒãžé¢é£ååãã¿ãŒã³)ãšããŠåãããšãå ±åãããŠãããè³æ¢å¡ã¢ãã«ã«ãããŠãHMGB1ã®çްè倿ŸåºãèªããããããHMGB1ã¯ãã¯ããã¡ãŒãžãè³çµç¹ã«æµžæœ€ããé ã«ã¯æ¶å€±ããççãåŒãèµ·ããåå ã«ã¯çŽæ¥ã¯é¢äžããŠããªãããšã確èªãããã
ãããŠä»åã®å®éšã§ã¯ãPrxã¯HMGB1ããé ããŠèè¡åŸ12æéãããŒã¯ã«çްèå€ã«æŸåºãããããšã«ãããè³çµç¹ã«æµžæœ€ãããã¯ããã¡ãŒãžã掻æ§åããããšã倿ããã®ã§ãã(ç»å7)ã
ç»å7ã¯ãè³èè¡ã«ãããççãåŒãèµ·ããå åãšããŠã®Prxã®åœ¹å²ã衚ããæš¡åŒå³ã§ãè³èè¡ã«ãããççã®çµæå€åã瀺ããçºç6æé以å ã®è¶ æ¥æ§æã«ã¯ãèè¡ã«é¥ã£ãè³çްèããHMGB1ãæŸåºãããããã¯è³è¡æ¶²é¢éã®ç Žå£ã«å¯äžãã圢ã ã
çºç12ïœ24æé以å ã®æ¥æ§æã«ã¯ãã¯ããã¡ãŒãžã®æµžæœ€ãèæã«ãªãããHMGB1ã®æŸåºã¯èŠãããªããªãã代ããã«ãèè¡ã¹ãã¬ã¹ã«ãã£ãŠçްèå ã§çºçŸããPrxãçŽ°èæ»ã«äŒŽã£ãŠçްèå€ã«æŸåºãããæµžæœ€ãããã¯ããã¡ãŒãžãTLR2ãTLR4äŸåçã«æŽ»æ§åããIL-23ãIL-1βãTNFαãç£çãIL-23ã¯ããã«é ããŠè³å ã«æµžæœ€ããå ç«çްèã®1çš®ã§ããT现è(γΎT现è)ããIL-17ãç£çããããããªãçµç¹å·å®³ãåŒãèµ·ãããšããæµãã§ããã
ä»åã®ç ç©¶ã«ãããè³æ¢å¡ã«ãããæ°ããªççã¡ã«ããºã ã倿ãããããã«ãè³æ¢å¡æ£è ã®è³å ã«ãããŠãåæ§ã«ãPrxã现èå€ã«æŸåºãããŠããããšãå ±åãããŠããããã®ããPrxã¯ãè³æ¢å¡ã«ãããæ²»çéå§å¯èœæéã®æ¯èŒçé·ãæ²»çã®ã¿ãŒã²ããã«ãªãåŸããšèããããä»åã®ç ç©¶ã®ç¥èŠãè³åäžå»çã«å¿çšãããããšãæåŸ ããããšãç ç©¶ã°ã«ãŒãã¯ã³ã¡ã³ãããŠããã


